-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
MaxCyte, Inc. (NASDAQ:MXCT) Shares Sold by River & Mercantile Asset Management LLP
MaxCyte, Inc. (NASDAQ:MXCT) Shares Sold by River & Mercantile Asset Management LLP
River & Mercantile Asset Management LLP trimmed its stake in MaxCyte, Inc. (NASDAQ:MXCT – Get Rating) by 13.1% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,100,000 shares of the company's stock after selling 315,500 shares during the quarter. MaxCyte comprises about 1.9% of River & Mercantile Asset Management LLP's holdings, making the stock its 7th biggest position. River & Mercantile Asset Management LLP owned 2.07% of MaxCyte worth $14,849,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other large investors have also bought and sold shares of the stock. BlackRock Inc. grew its holdings in shares of MaxCyte by 4.4% during the first quarter. BlackRock Inc. now owns 5,443,837 shares of the company's stock valued at $38,052,000 after buying an additional 229,373 shares during the last quarter. Vitruvian Partners LLP grew its holdings in shares of MaxCyte by 31.7% during the first quarter. Vitruvian Partners LLP now owns 4,385,670 shares of the company's stock valued at $30,656,000 after buying an additional 1,055,670 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of MaxCyte by 4.0% during the first quarter. Vanguard Group Inc. now owns 3,284,596 shares of the company's stock valued at $22,958,000 after buying an additional 126,906 shares during the last quarter. Massachusetts Financial Services Co. MA grew its holdings in shares of MaxCyte by 2.8% during the first quarter. Massachusetts Financial Services Co. MA now owns 1,872,197 shares of the company's stock valued at $13,087,000 after buying an additional 51,392 shares during the last quarter. Finally, American Century Companies Inc. acquired a new position in shares of MaxCyte during the first quarter valued at about $11,583,000. 66.40% of the stock is currently owned by institutional investors and hedge funds.
Get MaxCyte alerts:Analyst Upgrades and Downgrades
Separately, BTIG Research boosted their price target on shares of MaxCyte from $10.00 to $11.00 and gave the stock a "buy" rating in a report on Sunday, August 14th.
MaxCyte Stock Down 3.1 %
MaxCyte stock traded down $0.20 during midday trading on Tuesday, hitting $6.31. 4,625 shares of the stock were exchanged, compared to its average volume of 447,467. MaxCyte, Inc. has a 52-week low of $3.36 and a 52-week high of $16.28. The company has a market capitalization of $642.74 million, a PE ratio of -31.10 and a beta of 1.17. The stock's 50-day simple moving average is $5.43.Insider Buying and Selling
In related news, major shareholder Casdin Partners Master Fund, L sold 3,235,548 shares of the business's stock in a transaction dated Friday, July 1st. The shares were sold at an average price of $4.30, for a total transaction of $13,912,856.40. Following the transaction, the insider now directly owns 10,735,786 shares in the company, valued at $46,163,879.80. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 5.11% of the stock is owned by corporate insiders.
About MaxCyte
(Get Rating)
MaxCyte, Inc, a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.
Recommended Stories
- Get a free copy of the StockNews.com research report on MaxCyte (MXCT)
- The Two Things You Need To Know About Oracle's FQ1 Report
- Three Value Stocks For A Volatile Market
- 3 Energy Stocks Nearing Breakouts From Cup-Shaped Patterns
- Do These Dividend Achievers Deserve A Place In Your Portfolio?
- Darden Restaurants Takes the Low Road Against Inflation
Receive News & Ratings for MaxCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxCyte and related companies with MarketBeat.com's FREE daily email newsletter.
River & Mercantile Asset Management LLP trimmed its stake in MaxCyte, Inc. (NASDAQ:MXCT – Get Rating) by 13.1% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,100,000 shares of the company's stock after selling 315,500 shares during the quarter. MaxCyte comprises about 1.9% of River & Mercantile Asset Management LLP's holdings, making the stock its 7th biggest position. River & Mercantile Asset Management LLP owned 2.07% of MaxCyte worth $14,849,000 as of its most recent filing with the Securities and Exchange Commission.
River&Mercantile Asset Management LLP根據其最近提交給美國證券交易委員會的Form 13F文件,在第一季度將其在MaxCyte,Inc.(納斯達克代碼:MXCT-GET Rating)的股份削減了13.1%。該公司在本季度出售了315,500股票後,擁有2,100,000股公司股票。Maxcell約佔River&Mercantile Asset Management LLP所持股份的1.9%,使該股成為其第七大持倉。截至最近提交給美國證券交易委員會的文件,River&Mercantile Asset Management LLP擁有MaxCyte 2.07%的股份,價值14,849,000美元。
A number of other large investors have also bought and sold shares of the stock. BlackRock Inc. grew its holdings in shares of MaxCyte by 4.4% during the first quarter. BlackRock Inc. now owns 5,443,837 shares of the company's stock valued at $38,052,000 after buying an additional 229,373 shares during the last quarter. Vitruvian Partners LLP grew its holdings in shares of MaxCyte by 31.7% during the first quarter. Vitruvian Partners LLP now owns 4,385,670 shares of the company's stock valued at $30,656,000 after buying an additional 1,055,670 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of MaxCyte by 4.0% during the first quarter. Vanguard Group Inc. now owns 3,284,596 shares of the company's stock valued at $22,958,000 after buying an additional 126,906 shares during the last quarter. Massachusetts Financial Services Co. MA grew its holdings in shares of MaxCyte by 2.8% during the first quarter. Massachusetts Financial Services Co. MA now owns 1,872,197 shares of the company's stock valued at $13,087,000 after buying an additional 51,392 shares during the last quarter. Finally, American Century Companies Inc. acquired a new position in shares of MaxCyte during the first quarter valued at about $11,583,000. 66.40% of the stock is currently owned by institutional investors and hedge funds.
其他一些大型投資者也買入和出售了該股的股票。今年第一季度,貝萊德持有的MaxCyte股票增加了4.4%。貝萊德股份有限公司現在持有該公司5,443,837股股票,價值38,052,000美元,該公司在上個季度又購買了229,373股。今年第一季度,維特魯維亞合夥公司對MaxCyte股票的持有量增加了31.7%。在上個季度又購買了1,055,670股後,維特魯安合夥公司現在擁有4,385,670股該公司的股票,價值30,656,000美元。先鋒集團(Vanguard Group Inc.)第一季度增持MaxCyte股票4.0%。先鋒集團目前持有該公司3,284,596股股票,價值22,958,000美元,上一季度又購買了126,906股。今年第一季度,馬雲持有的MaxCyte股票增加了2.8%。馬雲現在持有該公司1,872,197股股票,價值13,087,000美元。馬雲在上個季度又購買了51,392股。最後,美國世紀公司在第一季度收購了MaxCyte的新頭寸,價值約11,583,000美元。66.40%的股票目前由機構投資者和對衝基金持有。
Analyst Upgrades and Downgrades
分析師升級和下調評級
Separately, BTIG Research boosted their price target on shares of MaxCyte from $10.00 to $11.00 and gave the stock a "buy" rating in a report on Sunday, August 14th.
另外,BTIG Research將MaxCyte的目標價從10.00美元上調至11.00美元,並在8月14日(星期日)的一份報告中給予該股“買入”評級。
MaxCyte Stock Down 3.1 %
Maxcell股票下跌3.1%
Insider Buying and Selling
內幕買賣
In related news, major shareholder Casdin Partners Master Fund, L sold 3,235,548 shares of the business's stock in a transaction dated Friday, July 1st. The shares were sold at an average price of $4.30, for a total transaction of $13,912,856.40. Following the transaction, the insider now directly owns 10,735,786 shares in the company, valued at $46,163,879.80. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 5.11% of the stock is owned by corporate insiders.
在相關新聞中,大股東Casdin Partners Master Fund,L在日期為7月1日星期五的交易中出售了3235548股該業務的股票。這些股票以4.30美元的平均價格出售,總成交金額為13,912,856.40美元。交易完成後,這位內部人士現在直接擁有該公司10,735,786股,價值46,163,879.80美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的,可以通過美國證券交易委員會網站訪問該文件。5.11%的股份由企業內部人士持有。
About MaxCyte
關於MaxCyte
(Get Rating)
(獲取評級)
MaxCyte, Inc, a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.
Maxcell,Inc.是一家全球生命科學公司,致力於下一代細胞療法的發現、開發和商業化。其產品包括:Expert ATx,一種用於中小規模轉基因的靜態電穿孔儀器;Expert STx,一種用於蛋白質生產和藥物開發的流動電穿孔設備,以及用於基於細胞分析的治療靶點的表達;Expert GTx,一種用於治療應用中大規模轉基因的流動電穿孔設備;以及Expert VLx,用於超大規模細胞工程。
Recommended Stories
推薦故事
- Get a free copy of the StockNews.com research report on MaxCyte (MXCT)
- The Two Things You Need To Know About Oracle's FQ1 Report
- Three Value Stocks For A Volatile Market
- 3 Energy Stocks Nearing Breakouts From Cup-Shaped Patterns
- Do These Dividend Achievers Deserve A Place In Your Portfolio?
- Darden Restaurants Takes the Low Road Against Inflation
- 免費獲取StockNews.com關於MaxCyte的研究報告(MXCT)
- 關於甲骨文的FQ1報告,你需要知道的兩件事
- 波動市場的三隻價值股
- 3個能源類股接近突破杯形格局
- 這些股息獲得者值得在你的投資組合中佔有一席之地嗎?
- 達頓餐廳走低通脹之路
Receive News & Ratings for MaxCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxCyte and related companies with MarketBeat.com's FREE daily email newsletter.
接收MaxCyte日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對MaxCyte和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧